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Summary.-The effect of misonidazole (MISO) on the cytotoxicity of cyclophos-
phamide (CY) was investigated in the mouse.
The response of the RIF-1 tumour was measured by growth delay and by cell
survival in a cloning assay. MISO enhanced the cytotoxicity of CY. For single
treatment, enhancement was maximal when MISO was given 30 min to 2 h before
CY. The enhancement ratio (i.e. the dose of CY alone divided by the dose of CY with
MISO required to cause the same response) increased with increasing dose of MISO
up to 250 mg/kg, but decreased with increasing dose of CY above 50 mg/kg. For 5
daily treatments, enhancement increased with CY dose up to -25 mg/kg/injection.
Survival of marrow stem cells was measured using the spleen-colony assay.
MISO did not enhance significantly the cytotoxicity of CY at doses under 100 mg/kg.
Enhancement was seen at higher doses, but the effect was less than in tumours.
CY reduced the number of circulating white blood cells. Neutrophils were most
severely depleted. The WBC count was slightly lower when CY was given in
combination with MISO than after CY alone, but the effect could be accounted for by
direct MISO cytotoxicity.
These experiments suggest that a therapeutic gain may be achieved if MISO is
combined with doses of CY in the clinical range.
From experiments performed to investigate the possible mechanisms involved,
we conclude that for the RIF-1 tumour the major effect of MISO is to inhibit the
repair from CY-induced potentially lethal damage.
IT IS WELL KNOWN that hypoxia pro-
tects cells from the cytotoxic effects of
radiation. Hypoxic cells in solid tumours
are therefore considered to be a problem
in the treatment ofcancer byradiotherapy.
There are also reasons why hypoxic cells
may be protected from chemotherapy.
Hypoxic cells and cells that are distant
from blood vessels tend to proliferate
slowly (Tannock, 1968; Koch et al., 1973;
Bedford & Mitchell, 1974; Hirst & Dene-
kamp, 1979) and may, therefore, be resis-
tant to most chemotherapeutic agents,
w^hich are more toxic to rapidly dividing
than to slowly dividing cells. Hypoxic
tumour cells may also receive lower con-
centrations of drugs, because of their dis-
tance from patent blood vessels. It has
also been reported that hypoxia per se
protects mammalian cells against the
cytotoxic action of bleomycin (Roizin-
Towle & Hall, 1978) and actinomycin D
(Adams, 1979).
Electron-affinic agents, such as the 2-
niitroimidazole, misonidazole [1-(2-nitro-
imidazole - 1 -yl) - 3 -methoxypropan- 2 -ol;
Ro-07-0582, MISO], have been shown to
be effective sensitizers of the cytotoxic
effects of radiation on hypoxic cells in
vitro and on tumours in vivo (Adams, 1977),
and clinical trials of MISO in combination
with radiation therapy are in progress in
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many centres (Thomlinson et al., 1976;
Dische et al., 1977; Urtasun et al., 1977).
Recently, Rose et al. (1979, 1980) have
shown that the cytotoxic effects of 2
alkylating agents, melphalan and cyclo-
phosphamide (CY), are enhanced by MISO
in mice. The response of the Lewis lung
carcinoma was enhanced to a greater
extent than marrow, suggesting an in-
creased therapeutic ratio for the combined
therapy.
In the present study the effect of MISO
on the response of the RIF-1 tumour to
CY was investigated in mice. The end-
points used to assess damage to the tumour
were growth delay in situ, and cell survival
assayed by plating in vitro after treatment
in vivo. To assess a possible therapeutic
gain, the responses of marrow stem cells
and white blood cells (WBC) were also
measured over the dose range used for the
tumour studies.
Some of the possible mechanisms for
the sensitization of this tumour to CY
by MISO were also investigated.
METHODS
Tumour studies
The RIF-1 tumour used in the present
study is a non-immunogenic sarcoma in its
syngeneic host, the C3H/Km mouse, which
has been developed for in vivo-in vitro assay
(Twentyman et al., 1980). Solid tumours were
produced in 3-4-month-old female C3H/Km
mice by inoculating 2 x 105 cells in a volume
of 0 05 ml into the base of the gastrocnemius
muscle. Tumour growth was followed by
measuring 2 leg diameters at right angles,
using a specially made Plexiglas gauge.
Tumour volume was estimated from a cali-
bration curve of tumour weight (- tumour
volume) plotted as a function of the product
of the 2 leg diameters (Twentyman et al.,
1979). Drug treatments were given when the
tumours were 300-600 mg.
The response to drug treatments was
investigated by 2 methods. For the growth-
delay assay, 10 animals were included in each
treatment group and tumours were measured
3 times a week. CY caused cessation ofgrowth
or regression, both of which were followed by
regrowth at rates identical to those in un-
treated mice. To compare treatments the
number ofdaysrequiredtoreach4 x themean
treatment volume was determined from
growth curves plotted for each animal.
Geometric means and standard errors were
calculated for each treatment group, as the
growth delays for individual tumours were
log-normally distributed.
For the cell-survival assay, tumours were
excised 24 h after treatment. This interval
was chosen as a compromise to allow most
or all of any potentially lethal CY damage to
be repaired whilst not allowing much time
for proliferation of surviving cells (Twenty-
man, 1977, 1979; Begg et al., 1980). Two to
four tumours were pooled and a single-cell
suspension was prepared by mincing the
tissue and incubating it with an enzyme
"cocktail" of 0-027% collagenase, 0.02%
DNAse and 0.05% pronase. The cells which
excluded trypan blue were counted with a
haemacytometer (cell yield 2 x 108/g) and
appropriate dilutions were plated into poly-
styrene Petri dishes containing complete
Waymouth's medium which included 15%
foetal calf serum. Colonies of at least 50 cells
were counted after 13 days' incubation at
37°C. The plating efficiency (PE) for control
tumours was - 30%. Surviving fractions were
calculated from either PE or numbers of
clonogeniccells pergram oftumour. There was
no significant difference between the results
obtained by the 2 methods of calculation,
so only surviving fractions estimated from
PE are shown in the figures. Details of the
method have been given elsewhere (Twenty-
man et al., 1980; Brown, 1977).
Normal-tissue studies
Marrow stem cells.-The survival ofmarrow
stem cells was determined using the spleen-
colony assay (Till & McCulloch, 1961). Mar-
row was removed from both femurs of 5-10
C3H/Km mice 24 h after treatment. The
survival of marrow stem cells did not alter
significantly when the interval between the
drug treatments and excision was varied
from 1 to 24 h (data not shown). An appro-
priate number ofmarrow cells which excluded
trypan blue were injected in 0-2 ml into the
tail veins of 8-10 preirradiated (8-5 Gy whole
body) recipients. Spleen colonies were counted
at 8 days and the surviving number of stem
cells per femur was estimated.
White cells. Blood samples (5 ,ul) were
taken from the tail and added to 95 ,ul of
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2% glacial acetic acid to lysethe erythrocytes.
The resulting suspension of leucocytes was
counted with a haemacytometer. Four to five
mice were used for each treatment group. In
some experiments a blood smear was also
made. The smear was stained withLeichman's
stain and the different populations of leuco-
cytes were counted.
Drugs
Drugs were dissolved in physiological
saline. Concentrations of injections were
varied so that a constant injection volume
could be used for each drug. Solutions of
MISO (0 04 ml/g body wt) and CY (0.01 ml/g
body wt) were injected i.p. The 2-nitroimida-
zole amide, SR-2508, was injected via the tail
vein. The doses of nitroimidazoles used were
below maximum tolerated doses for C3H/Km
mice. The maximum single dose of CY used
(200 mg/kg) was about two-thirds of the
maximum tolerated dose for C3H/Km mice
bearing RIF-1 tumours (Twentyman et al.,
1980). Combining this dose of CY with the
doses of MISO used in this study had no
effect on animal survival. However, 5/9 mice
died after 5 daily treatments of 300 mg/kg
MISO combined with 50 mg/kg CY (total
dose of MISO and CY. 1500 and 250 mg/kg
respectively) compared with 2/9 after 5 daily
treatments of 50 mg/kg CY (same total dose)
given with saline.
RESULTS
Response of RIF-1 tumours
Effect of cyclophosphamide dose.-Mice
bearing RIF-1 tumours were injected
with MISO (750 mg/kg) or saline 30 min
before various single doses of CY. The
effect on the tumour response to CY is
seen in Fig. 1. The dose of MISO had no
effect on tumour growth or tumour-cell
survival, but it enhanced the cytotoxicity
of CY as measured by both endpoints.
The data for growth delay indicate that
MISO is strictly dose-modifying for CY
doses below 50 mg/kg, but not above 50
mg/kg. A single regression line was fitted
through all the data for CY alone, whereas
2 lines (one for 0-50 mg/kg CY and the
other for 50-150 mg/kg) were fitted for
the combined treatment. Enhancement
ratios (ER), defined as the dose of CY
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FIG. 1. The effect of misonidazole (MISO)
on the response of the RIF-1 tumour to
cyclophosphamide (CY). MISO (750 mg/kg,
0) or saline (0) was given 30 min before
single doses of CY. Upper diagram: growth
delay. Symbols represent geometric means
for 10 animals + s.e. Data from 2
experiments have been combined. Lower
diagram: cell survival. Tumours were
removed 24 h after CY and 2 tumours were
combined to-determine surviving fractions.
D0
alone divided by the dose of CY given
with MISO required to cause the same
growth delay, were calculated for various
doses of CY alone. These ratios are given
in Table I. It can be seen that the values
decreased with doses of CY greater than
75 mg/kg.
Cell-survival curves for CY given alone
or 30 min after MISO (750 mg/kg) are also
shown in Fig. 1. These curves were essen-
tially exponential, so regression lines were
drawn through data for 0-100 mg/kg of
CY alone and, for comparison with growth
delay, through those for 0-50 mg/kg of
CY given with MISO. Enhancement ratios,
calculated as the ratio of the Do obtained
for CY alone to that for CY combined
with MISO, were 1-72+0-16 and 1P30+
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TABLE I.-Enhancement ratios for RIF-1
tumours, calculated from growth delay
after single treatments
Dose of
CY
alone
(mg/kg)
25
50
75
100
125
150
Dose of CY given
30 min after 750
mg/kg MISO
(mg/kg)
11-5
24-3
37*0
56-5
87-0
117-5
ER
2-1
2-1
2-1
1-8
1-4
1-3
0 18 in 2 experiments. Combining the
data from the 2 experiments gave an
ER of 1P53 + 0-20.
Effect of interval between drugs.-Fig. 2
shows the effect of varying the time be-
tween MISO and CY treatments. Growth-
delay and cell-survival assays gave similar
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results. Enhancement of the response to
CY was seen if the drugs were given
simultaneously, but the maximum effect
was observed when MISO was given 0-5-2
h before CY. The interaction subsequently
decreased and was lost by 8-24 h.
In one experiment (data not shown)
750 mg/kg MISO was given at various
times after 50 mg/kg CY. The interaction,
as measured by cell survival, was lost if
the interval between CY and MISO was
30-60 min.
Effect of misonidazole dose.-Various
doses ofMISO were given 30 min before a
50mg/kgdoseofCY. Theresults are shown
in Fig. 3. For growth delay, enhancement
reached a plateau at a MISO dose of 250
mg/kg. For tumour-cell survival, enhance-
ment increased with dose ofMISO, with a
suggestion ofa plateau at 500 mg/kg.
There is an apparent discrepancy be-
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Fic. 2. The effect of increasing the interval
between doses of MISO (750 mg/kg) and
CY on the response of RIF- 1 tumours.
Upper diagram: growth delay. CY dose
50 mg/kg. Symbols represent geometric
means for 10 animals and standard errors
are shown. Lower diagram: cell survival.
CY dose, 33-3 mg/kg. Tumours were re-
moved 24 h after CY and 2 tumours were
combined to determine surviving fractions.
A, MISO alone; 0, CY alone; 0, MISO
+CY; Lii, saline alone.
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FIG. 3.-The response of RIF-1 tumours to
combined MISO and CY (50 mg/kg)
was given 30 min after MISO, as a function
ofthe dose ofMISO. Upperdiagram: growth
delay. Each point represents the geometric
means for 10 animals + s.e. Lower diagram:
cell survival. Tumours were removed 24 h
after CY and 2 tumours were combined to
calculate cell survival. 0, MISO+CY; C.
saline alone; A, MISO alone.
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tween the conclusions of the 2 assays.
In the case ofregrowth delay, the enhanc-
ing effect of MISO appears essentially as
great at 250 mg/kg as at higher doses,
whereas in the cell-survival experiments
much of the enhancing effect appears to
be lost at 250 mg/kg. Since each of the
points for cell survival depend on one cell
suspension, whereas the regrowth delays
were estimated from 10 independently
analysed tumours, more weight should be
given to the regrowth experiments. Des-
pite the discrepancy, however, it can be
concluded that enhancement of the effect
of 50 mg/kg CY is seen at MISO doses of
125 and 250 mg/kg.
Effect offractionation.-Tumour growth
after 5 daily treatments of CY given alone
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FIG. 4.-The effect of combining MISO and
CY in fractionated treatments on the
growth of the RIF-1 tumour. MISO at
300 mg/kg (A) or saline (A) was given
30 min before each of 5 daily doses of CY.
Points indicate geometric means + s.e. for
10 mice (except data for 250 mg/kg CY,
see Methods).
TABLE II.-Enhancement ratios for RIF-1
tumours, calculated from growth delay
after 5 daily treatments
Total dose
of CY
alone
(mg/kg)
50
100
150
200
250
Total dose of CY
with 300 mg
MISO/kg/day
(mg/kg)
50
67
95
125
150
ER
1-0
1-5
1-6
1-6
1-7
Normal tissues
Marrow stem cells.-The effect of MISO
on CY cytotoxicity to marrow stem cells
is shown in Fig. 5. All these data were
obtained with a MISO dose of 750 mg/kg
30 min before CY. This interval gave the
lowest survival of tumour cells (Fig. 2)
and marrow cells (data not shown) at a
high CY dose. It can be seen (Fig. 5) that
at CY doses > 100 mg/kg, MISO en-
hanced the cytotoxicity of CY, but the
effect was much less than that observed
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or combined with MISO is shown in Fig. 4.
The dose of MISO (300 mg/kg) was given
30 min before each CY dose, and caused
no animal toxicity when given in the 5
daily fractions with any CY dose. En-
hancement was found at doses of CY
greater than -10 mg/kg/day (i.e., total
dose , 50 mg/kg). Enhancement ratios are
given in Table II, and show that their
values increased sharply as the CY dose
was increased to 20 mg/kg/day.
10-4
50 100 150 200
DOSE OF CYCLOPHOSPHAMIDE (mg/kg)
250
Fma. 5. The effect of MISO (750 mg/kg)
on the response of marrow stem cells to CY.
MISO (*) or saline (0) was given 30 min
before CY. Results for several experiments
are shown. Surviving fractions were calcu-
lated from the mean number of colonies per
spleen. The lines through the data are drawn
by eye.
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in the tumour. At CY doses < 100 mg/kg,
there was no evidence of enhancement.
The relationship between CY dose and
cell survival was not exponential. The
survival curve appeared to bend down-
wards continuously over the range ofdoses
used.
The dose-limiting toxicity of CY is
probably not due to depletion of CFU-S,
but to an effect on a more differentiated
population of cells. However, a large
enhancement by MISO could make it the
former.
White cells.-The number of WBC in
the peripheral blood was counted for up
to 8 days after a large single dose ofCY or
saline. Although the number of cells
varied even in the control animals, there
was an obvious decline in the WBC count
after CY until a minimum was reached at
4 days. The WBC count subsequently
recovered.
To investigate the effect ofMISO on the
response to a range ofCY doses, WBC were
counted 4 days after treatment; i.e. at
N.
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FIG. 6. The effect of MISO (750 mg/kg) on
the response ofwhite cells in the peripheral
blood to CY. MISO (solid symbols) or saline
(open symbols) was given 30 min before
CY. Note that the ordinate for the total
white cell count has been raised to avoid
the total white curve becoming super-
imposed over that of the lymphocyte curve
at high CY doses. Data from 4 experiments
have been pooled.
the time of maximum depletion. MISO
(750 mg/kg) or saline was given 30 min
before various doses ofCY.
Data obtained from several experiments
are shown in Fig. 6. The experiments were
carried out on both tumour-bearing and
non-tumour-bearing animals, and as no
consistent difference was seen between the
responses, the data from both series of
experiments were pooled. Counts of total
WBC and of the 2 major subpopula-
tions, lymphocytes and neutrophils, are
shown. MISO alone reduced the number
of circulating WBC by 20%, an effect
entirely due to depletion of the neutrophil
population. Lymphocytes were unaffected
by MISO alone at the dose used (750
mg/kg). With increasing dose of CY, the
total number of WBC decreased exponen-
tially. Both lymphocytes and neutrophils
were affected, but neutrophils showed
much greater sensitivity. No neutrophils
were seen in any of the blood smears after
60 mg/kg of CY plus MISO. The combina-
tion with MISO reduced the number of
WBC at all doses ofCY, but the effect was
consistent with direct MISO cytotoxicity,
and did not change the slope of the dose-
response curve.
Study ofmechanisms
Metabolic effects.-Thermocouples were
used to measure rectal temperatures in
unanaesthetized C3H/Km mice for 12 h
after various drug treatments. The effect
of MISO was compared with that of SR-
2508, a 2-nitroimidazole of equal electron-
affinity but lower toxicity (Brown &
Workman, 1980). In contrast to MISO,
SR-2508 undergoes little or no oxidative
metabolism in vivo (White et al., 1980).
MISO at 750 mg/kg alone or combined
with CY caused a temperature drop of
about 5TC, whereas SR-2508 given in the
same molar doses (800 mg/kg) had no
effect on temperature (Fig. 7). SR-2508,
however, enhanced the cytotoxicity of
CY to RIF-1 tumour cells, as shown in
Fig. 8. The magnitude of the enhancing
effect was comparable to that obtained for
MISO, but the reduced interaction as the
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FIG. 7.-The effectofvarioustreatmentsonthe
rectal temperature of unanaesthetized
C3H/Km mice. MISO and SR-2508 were
given in equimolar doses. The shaded areas
indicate the mean of values for 4 control
mice obtained during the 12 h ofthe experi-
ment ( 0) +s.e. Other symbols indicate the
average +range for 2 animals.
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FIG. 8.-The enhancement of CY (50 mg/kg)
cytotoxicity to RIF-1 tumour cells by
SR-2508 (800 mg/kg, A). Tumours were
removed 24hafter CYtreatment and 2 were
combined to estimate cell survival. A,
SR-2508 alone; 0, CY alone.
interval between sensitizer and CY was
increased occurred more rapidly for SR-
2508, as might be expected, since the
elimination half-life of SR-2508 is con-
siderably less than that of MISO (Brown
& Workman, 1980). Phenobarbitone at
lo-
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9.-The effect of MISO (750 mg/kg) on
the repair of potentially lethal CY damage
by RIF-1 tumour cells. MISO was given
30 min before CY and tumours were re-
moved at various times after the CY dose.
Four tumours were combined to determine
cell survival. Results of three experiments
are shown: A V, CY alone (50mg/kg);
A, MISO+CY (50 mg/kg); 0, CY
alone (75 mg/kg); 0, MISO+CY (75
mg/kg).
50 mg/kg, which caused a temperature
drop of about 7°C had no enhancing effect
on CY cytotoxicity (data not shown).
Potentially lethal damage.-The repair
of potentially lethal damage was investi-
gated by removing RIF-1 tumours at
different times after CY doses of 50 and
75 mg/kg. Fig. 9 shows the results of 3
experiments. Repair of potentially lethal
CY damage was observed after both CY
dose levels. MISO (750 mg/kg) given 30
min before CY inhibited this repair.
The data also suggest that survival in
the MISO-treated groups continues to fall
between 2 and 6 h after injection of CY.
If this is real it could reflect progressive
killing of tumour cells by residual CY,
an effect which would not normally be
seen due to the competing repair ofpoten-
tially lethal damage.
DISCUSSION
The question of therapeutic gain
The present study shows that MISO,
at doses which have no detectable effect
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Fia. 10. Enlhaneement ratios for MISO
combined with CY plotte(l as a function
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MISO (750 mg/kg) 30 min before single
doses of CY: (a) Growtlh of RIF-1 tumours;
(e) Survival of RIF-1 tumour cells; (d) Sur-
vival of marrow stem cells. MISO (300
mg/kg) 30 min before eaclh of 5 daily
fractions of CY: (b) Growtlh of RIF-1
tumours.
alone, enhances the cytotoxic effect of CY
in vivo. A comparison of enhancement
ratios (ER) for the different tissues and
endpoints used is shown in Fig. 10. For
single treatments, MISO at 750 mg/kg was
given at the optimal time of 30 min before
injection of CY (Fig. 2). The ER for
tumour-growth delay was -2 0 for CY
doses up to 75 mg/kg. Above these doses
there was no additional sensitization, so
that ER steadily decreased with increasing
doses of CY. Because the RIF-1 tumour
cells were very sensitive to combined
treatment, ERs could only be determined
for low doses of CY in the in vivo-in vitro
assay. The ERs obtained from these ex-
periments were less than those obtained
for comparable doses using growth delay
as the endpoint, and showed more varia-
bility between experiments. This will be
discussed in more detail below.
Both the endpoints used to assess the
sensitivity of normal tissues to the dif-
ferent treatments involved populations of
the haemopoietic system. However, the
results for marrow stem cells (CFU-S) as
assayed in the spleen-colony assay, and for
mature white cells in the peripheral blood,
showed some differences. Whereas MISO
alone at 750 mg/kg had no cytotoxic effect
on marrow stem cells, it reduced the num-
ber of neutrophils, so that the total
WBC count decreased by 20%. The lack
of an effect ofMISO alone at high doses on
mouse CFU-S is in agreement with the
findings of Turner et al. (1980), though the
same group has reported preliminary
findings that therapeutic doses of MISO
in patients cause a significant reduction in
CFU-S assayed in vitro (Allalunis et al.,
1979). In neither of these studies was the
effect on the peripheral white count noted.
However, significant neutropenia has been
reported in women treated for vaginal
trichomoniasis with total doses of 7.5 g
metronidazole givenover 10days (Lefebvre
& Hesseltine, 1965).
When MISO was combined with CY, a
slight enhancement of the cytotoxicity to
CFU-S at CY doses > 100 mg/kg was seen,
but there was no modification of the
response of WBC in general or neutrophils
in particular to CY. The lack of correlation
between the 2 cell populations probably
reflects the complexity of the divisions
and differentiation which occur during
haemopoiesis. In either case, any increased
effect seen by the addition of MISO was
much less than that observed in the RIF-1
tumour, so that there was a positive thera-
peutic gain.
MISO also enhanced the growth delay
of the RIF-1 tumour after fractionated
doses of CY. In contrast to the results for
single treatments, however, ERs for
repeated treatment increased with increas-
ing CY dose, and the maximum ER at
50 mg/kg/fraction of CY with MISO was
less than that for single treatments.
Enhancement by MISO of the response
to CY has been observed by other authors
in 6 murine tumours (Clement et al., 1980;
Martin & McNally, personal communica-
tion; Rose et al., 1980; Tannock, 1980;
Twentyman, 1981). In general a thera-
peutic gain has been obtained by combin-
ing MISO and CY, maximum ERs for
tumours being about 2, compared with
10-105 for lethality (Clement et al., 1980;
Martin & McNally, personal communica-
tion; Twentyman, 1981), marrow stem-
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cell survival (Clement et al., 1980; Rose
et al., 1980; and bladder epithelium
(Martin & McNally, personal communica-
tion). Tannock (1980), however, has con-
cluded from his experiments with the
KHT tumour that there is no therapeutic
gain in adding MISO to CY. His conclusion
was based on comparisons of weight loss,
mouse toxicity and tumour growth delay
after injection of 200 mg/kg CY alone or
after 75 mg/kg CY combined with 1000
mg/kg MISO. We feel, however, that this
is a misleading conclusion. Whereas there
may well be no therapeutic gain at 200
mg/kg of CY, this does not preclude one
at lower doses. In fact our data show a
high therapeutic gain at doses of less than
75 mg/kg ofCY alone, but no gain at doses
in excess of 150 mg/kg (Fig. 10). Such doses
are higher than clinical usage, and the
greater tumour effect than marrow toxicity
at lower doses of CY suggests that the two
agents may be used to therapeutic advan-
tage in the clinic.
]lechanism.s
Possible mechanisms for the enhance-
ment ofCY cytotoxicity byMISO include:
(1) selective sensitization of hypoxic cells
to CY by MISO; (2) selective killing of
hypoxic cells by MISO; (3) changes in the
pharmacokinetics of CY induced by MISO;
and (4) inhibition of the repair of potenti-
ally lethal CY damage by MISO.
The first possibility (selective sensitiza-
tion of hypoxic cells) could explain the
differential effect of combined treatment
on tumours and normal tissues, since there
are hypoxic cells in tumours but not in
normal tissues. The dependence of ER on
CY dose, however, is not expected for
sensitization of a small population of
resistant hypoxic cells. By analogy to
radiation damage, for which it is estab-
lished that MISO sensitizes only radio-
resistant hypoxic cells, one might predict
an increase in ER to a plateau with in-
creasing CY dose. Actually there was a
decrease in ER as the dose ofCY increased.
The same absence of further sensitization
when MISO was added to doses of CY
above - 50 mg/kg has been seen for the
RIF-1 tumour by Twentyman (1981), and
for the EMT6 tumour by ourselves (Brown
et al., in preparation). The fact that this
result is different from that when MISO
is combined with radiation, suggests that
MISO does not sensitize only hypoxic cells
to the cytotoxic effect of CY.
The second possibility (that MISO
selectively kills the hypoxic cells which
are resistant to CY) can be ruled out by
2 observations. First, such an effect
would not produce a constant enhance-
ment by MISO ofthe response to low doses
of CY. Second, no cytotoxicity to the
tumours was seen with MISO alone, either
by the in vivo-in vitro assay (Fig. 1) or by
histological examination of the treated
tumours.
The third possibility (that MISO could
change the pharmacokinetics of CY,
leading to a prolongation ofactive metabo-
lites in the serum) has received support
from Tannock (1l980). This investigator
has shown that MISO delays the loss of
active metabolites of CY, by testing the
cytotoxicity of serum from treated mice
against CHO cells in vitro. -However,
although this might account for the small
enhancement of the killing of CFU-S seen
at high CY doses, it seems difficult to
explain the differential effect on tumour
cells and normal cells, seen by ourselves
and others, in these terms. Additional
evidence against this mechanism is the
possibility of effects on CY pharmaco-
kinetics by competition between the drugs
for catabolic sites or from a general lower-
ing of metabolic rates by hypothermia.
Since it is probable that both CY and
MISO undergo oxidative metabolism by
liver microsomal mixed-function oxidases,
and MISO is known to cause a reduction
in body temperature, heart and respiration
rates in the mouse (Gomer & Johnson,
1979; Conroy et al., 1980), such a mechan-
ism might appear reasonable. However,
our finding that the 2-nitroimidazole
radiosensitizer, SR-2508, which neither
undergoes oxidative metabolism (White
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et al., 1980) nor causes a temperature de-
crease in mice (Fig. 7), sensitizes the RIF-1
tumour to CY, suggests that interference
with CY metabolism is not the primary
mechanism for chemosensitization.
The fourth possibility is presented in
Fig. 9. This shows repair of potentially
lethal CY damage in the RIF-1 tumour,
which was inhibited by MISO. The lower
ER based on cell survival than on re-
growth delay is also consistent with these
data. Tumours removed to assay cell sur-
vival 24 h after treatment may have re-
paired less potentially lethal damage
(PLD) than if they had been left in situ.
Inhibition of repair of PLD by MISO
would thus have an apparently greater
effect on growth delay than on cell sur-
vival. Inhibition of repair of potentially
lethal CY damage by MISO has also been
found in the WHFib sarcoma grown s.c.
(Martin & McNally, personal communica-
tion). Small WHFib lung tumours, how-
ever, showed no repair of PLD with CY.
ERs for these lung tumours were less than
those for the s.c. tumours, but similar to
those for normal tissues. It is possible,
therefore, that the sensitizing effect of
MISO the cytotoxicity of CY to some
tumours is due to an inhibition of repair
of PLD. Not all tumours that can be
sensitized to CY cytotoxicity by MISO,
however, exhibit repair of CY PLD. The
EMT6/St/lu tumour appears to be one
such example (Brown et al., in prepara-
tion).
Thus we cannot at this time be conclu-
sive about the mechanism involved in
sensitization of tumours to CY by MISO.
Nevertheless, our data indicate that
neither a selective effect on hypoxic cells
(neither sensitization nor killing), nor
altered pharmacokinetics, are of primary
importance and that, at least for some
tumours, inhibition of repair of CY PLD
by MISO may be involved.
The question of therapeutic gain must
be approached with caution. The animal
studies show that the combination of
MIS with low doses of CY may give a
therapeutic gain, when evaluated by
comparing CY ERs for tumours with
those for several normal tissues. Although
the overall sensitivity ofthe WBC popula-
tion does not appear to prevent the effec-
tive combination of MISO with CY, the
extreme sensitivity of neutrophils to CY
alone, and the fact that MISO alone at
750 mg/kg kills 500o of them, could com-
promise the ability to combat infection
further than the total WBC would suggest.
Although we have demonstrated that
the addition of MISO produces a thera-
peutic gain at some doses of CY, it is too
early to say whether any clinical use will
result from their combination. The dose
ofMISO (750 mg/kg) used in most present
experiments is greater than the likely
clinical doses. Unlike the case with radia-
tion, however, it is not clear that peak
plasma levels alone determine the magni-
tude of the present interaction. For
example, we have shown with the RIF-1
tumour that plasma levels sustained for
5 h before CY injection give a larger ER
(2*0) than the same plasma levels main-
tained for only 0*5 h (ER = 1.4). Thus total
tissue exposure could be of importance
and the 10-fold longer elimination half-life
of MISO in man than in mice will give
much longer tissue exposure in human
than in murine tumours. In addition, we
do see some enhancement of the CY effect
even at MISO doses of 125 mg/kg, and
these give peak plasma levels which can
be attained in man. Also the possibility
of enhancement of MISO-induced neuro-
toxicity by CY remains. In this respect,
the use of less neurotoxic drugs such as
SR-2508 that sensitize to CY may be an
advantage.
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